increased cortisol levels were observed in both healthy humans and type 1 diabetes patients to whom GLP-1 had been administered peripherally [76]
A pharmacokinetic study in rats found that oral administration produced substantial plasma concentrations, with a maximum concentration of 2252 ng/mL and an elimination half-life of approximately 6.9 hours
Abdulmalik, S., Gallo, J., Nip, J., Katebifar, S., Arul, M., Lebaschi, A., et al
The agreement between the two pharmaceutical manufacturers and the federal government was announced on November 6, 2025 in a White House fact sheet from the White House and press releases from Eli Lilly and Novo Nordisk